Study of AK119 in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to
Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in
Subjects with Advanced or Metastatic Solid Tumors.